Skip to main content
SpringerLink
Log in

Initial micafungin may be cost saving for systemic Candida

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 euros

Reference

  • van Engen A, et al. "De-escalation" strategy using micafungin for the treatment of systemic Candida infections: budget impact in France and Germany. ClinicoEconomics and Outcomes Research 2017: 763-774, No. 9, 5 Dec 2017. Available from: URL: https://doi.org/10.2147/CEOR.S141548

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Initial micafungin may be cost saving for systemic Candida . PharmacoEcon Outcomes News 793, 18 (2017). https://doi.org/10.1007/s40274-017-4578-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4578-3

Search

Navigation